Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000694371 | SCV000822813 | uncertain significance | Multiple gastrointestinal atresias | 2024-12-16 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 397 of the TTC7A protein (p.Val397Ile). This variant is present in population databases (rs146284515, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with TTC7A-related conditions. ClinVar contains an entry for this variant (Variation ID: 572873). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt TTC7A protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV000694371 | SCV001520480 | uncertain significance | Multiple gastrointestinal atresias | 2019-06-21 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Mayo Clinic Laboratories, |
RCV001509147 | SCV001715704 | uncertain significance | not provided | 2019-08-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004025192 | SCV004974409 | uncertain significance | Inborn genetic diseases | 2022-03-31 | criteria provided, single submitter | clinical testing | The c.1189G>A (p.V397I) alteration is located in exon 9 (coding exon 9) of the TTC7A gene. This alteration results from a G to A substitution at nucleotide position 1189, causing the valine (V) at amino acid position 397 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
3billion, |
RCV004723087 | SCV005328678 | likely benign | Gastrointestinal defects and immunodeficiency syndrome 1 | 2024-09-20 | criteria provided, single submitter | clinical testing | The homozygous variant was found in patients diagnosed with another variant in a different gene, with no symptoms related to the gene containing the homozygous variant. |